Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Phylonix Pharmaceuticals, a biotechnology company, has received a broad patent from the US Patent and Trademark Office for assessing the toxicity of pharmaceutical test agents on cardiovascular functions in zebrafish.
Subscribe to our email newsletter
The new US patent, which has 22 claims, includes assessment of heart rate in zebrafish and use of microplates for high-throughput screening.
Patricia McGrath, president and CEO of Phylonix, said: “Although the pharmaceutical industry and the FDA have increased scrutiny of drug-related cardiotoxicity, especially drug effects on prolonging QT interval, there is currently a gap in technologies for preclinical cardiotoxicity assessment. Our panel of zebrafish-based assays will bridge this gap by enabling thorough assessment of cardiotoxicity during early stages of drug development.”
“This award complements our previously issued patents for assessing angiogenesis, apoptosis, and toxicity in zebrafish, use of high-throughput screening methods, and transplantation of human cells for drug testing and disease modeling.”